# Multicentre Phase III Erythropoietic Protoporphyria Study

> **NCT04053270** · PHASE3 · COMPLETED · sponsor: **Clinuvel Pharmaceuticals Limited** · enrollment: 100 (actual)

## Conditions studied

- Erythropoietic Protoporphyria

## Interventions

- **DRUG:** Afamelanotide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04053270
- **Lead sponsor:** Clinuvel Pharmaceuticals Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2009-12-09
- **Final completion:** 2009-12-09
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2019-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04053270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04053270, "Multicentre Phase III Erythropoietic Protoporphyria Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04053270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*